Internal Medicine Alert – September 30, 2013

September 30, 2013

• Effect of Dabigatran on Referrals to and Switching from Warfarin

  Dabigatran has been demonstrated to decrease the rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) by one-third, while also decreasing the rate of intracranial bleeding by two-thirds compared with warfarin.

  Read more

• Omega 3s and the Prostate: Good or Bad?

  The role of omega-3 fatty acids in prostate cancer risk has been inconsistent and it has been difficult to draw practical and clinically useful conclusions from the research.

  Read more

• Azithromycin — The Heart of the Matter Redux: Pre-existing Risks Tell the Tale

  Svanström and colleagues in copenhagen examined the risk of cardiovascular deaths in association with azithromycin use in a nationwide historical cohort study of Danish adults aged 18-64 years.

  Read more

• Pharmacology Update: Brimonidine Tartrate Topical Gel (Mirvaso®)

  A highly selective alpha-2 adrenergic receptor agonist has been approved by the FDA for the treatment of persistent facial erythema of rosacea in adults.

  Read more

• Clinical Briefs By Louis Kuritzky

  Read more